JPMorgan Chase & Co. Buys 144,181 Shares of Urogen Pharma $URGN

JPMorgan Chase & Co. raised its stake in shares of Urogen Pharma (NASDAQ:URGN) by 36.9% during the third quarter, Holdings Channel reports. The firm owned 534,545 shares of the company’s stock after buying an additional 144,181 shares during the quarter. JPMorgan Chase & Co.’s holdings in Urogen Pharma were worth $10,664,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the stock. Soleus Capital Management L.P. bought a new stake in shares of Urogen Pharma during the 2nd quarter valued at about $29,934,000. SG Americas Securities LLC lifted its holdings in Urogen Pharma by 607.1% in the second quarter. SG Americas Securities LLC now owns 1,149,081 shares of the company’s stock worth $15,742,000 after buying an additional 986,567 shares during the period. Orbimed Advisors LLC bought a new stake in Urogen Pharma during the 2nd quarter valued at approximately $6,554,000. Walleye Capital LLC purchased a new position in shares of Urogen Pharma during the 2nd quarter worth approximately $4,742,000. Finally, Panagora Asset Management Inc. raised its position in shares of Urogen Pharma by 181.9% in the 2nd quarter. Panagora Asset Management Inc. now owns 261,785 shares of the company’s stock worth $3,586,000 after acquiring an additional 168,908 shares in the last quarter. 91.29% of the stock is currently owned by institutional investors.

Insider Activity

In other news, insider Mark Schoenberg sold 7,373 shares of the company’s stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $19.69, for a total value of $145,174.37. Following the transaction, the insider owned 144,985 shares in the company, valued at approximately $2,854,754.65. This represents a 4.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, General Counsel Jason Drew Smith sold 7,479 shares of the firm’s stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $19.69, for a total transaction of $147,261.51. Following the sale, the general counsel directly owned 51,326 shares of the company’s stock, valued at $1,010,608.94. This trade represents a 12.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 4.70% of the stock is currently owned by insiders.

Key Stories Impacting Urogen Pharma

Here are the key news stories impacting Urogen Pharma this week:

• Positive Sentiment: Urogen’s quarterly report beat EPS expectations (smaller loss than forecast), prompting an early gap‑up in the shares as investors cheered the outcome. Read More.
• Positive Sentiment: D. Boral Capital assigned a “Buy” rating to URGN, which supports demand from investors looking for upside in the drug’s commercial rollout and can help short‑term sentiment. Read More.
• Neutral Sentiment: Coverage discusses UroGen weighing the commercial success of ENVISION and an expanded loan to support its bladder cancer push — this could fund growth but also increases leverage and execution risk, so the market reaction is ambiguous. Read More.
• Negative Sentiment: HC Wainwright substantially lowered near‑term EPS estimates: Q2 2026 to ($0.64) from ($0.42), Q3 2026 to ($0.42) from ($0.14), Q4 2026 to ($0.33) from $0.01, and cut FY2026 to ($1.99) from ($1.18). (They did slightly raise Q1 2026 to ($0.60) from ($0.63) and project FY2027 at $0.45.) These deeper downgrades to 2026 earnings signal weaker near‑term profitability expectations and are the main negative catalyst weighing on the stock. Read More.

Wall Street Analyst Weigh In

URGN has been the topic of several research reports. Wall Street Zen upgraded Urogen Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Urogen Pharma in a research report on Wednesday, January 21st. D. Boral Capital reaffirmed a “buy” rating and issued a $33.00 target price on shares of Urogen Pharma in a research report on Monday. Finally, Oppenheimer reiterated an “outperform” rating on shares of Urogen Pharma in a research note on Monday. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Urogen Pharma presently has a consensus rating of “Moderate Buy” and a consensus target price of $33.29.

Urogen Pharma Trading Down 2.7%

Urogen Pharma stock opened at $19.61 on Friday. Urogen Pharma has a 12 month low of $3.42 and a 12 month high of $30.00. The company has a market capitalization of $954.61 million, a price-to-earnings ratio of -6.13 and a beta of 1.34. The business’s fifty day simple moving average is $20.94 and its two-hundred day simple moving average is $20.86.

Urogen Pharma (NASDAQ:URGN) last issued its quarterly earnings results on Monday, March 2nd. The company reported ($0.54) earnings per share for the quarter, beating the consensus estimate of ($0.66) by $0.12. The company had revenue of $37.84 million for the quarter, compared to the consensus estimate of $39.92 million. On average, equities research analysts predict that Urogen Pharma will post -3.12 EPS for the current year.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.